产品
编 号：F761039
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 876387-05-2
产品详情
生物活性：
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes.
体内研究：
Teplizumab (0.24 mg/kg, i.p.) induces migration of human CD4 T cells to the lamina propria and ablated the treatment effects of the drug on graft survival in NSG mice.Animal Model:NOD/SCID IL2γc-/- (NSG) mice (a tolergenic humanized mouse model)
Dosage:0.24 mg/kg, 5 μg
Administration:Intraperitoneal injection (i.p.)
Result:Decreased CD4:CD8 ratio in the peripheral blood from 2.03 to 1.01, p < 0.05.Decreased circulating hCD4 cells in the peripheral blood. Decreased in the proportion of T cells in the bone marrow and lung. Increased in the total number of human CD45+ cells infiltrating the lamina propria of the small intestine.
体外研究：
Teplizumab (10 ng/mL-10 μg/mL, 5 days) induces human CD8+ T-cell proliferation. Teplizumab (6 days) increases the expression of CD25 and intracellular CTLA4 on CD8+ cells (freshly isolated PBMCs).
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes.
体内研究：
Teplizumab (0.24 mg/kg, i.p.) induces migration of human CD4 T cells to the lamina propria and ablated the treatment effects of the drug on graft survival in NSG mice.Animal Model:NOD/SCID IL2γc-/- (NSG) mice (a tolergenic humanized mouse model)
Dosage:0.24 mg/kg, 5 μg
Administration:Intraperitoneal injection (i.p.)
Result:Decreased CD4:CD8 ratio in the peripheral blood from 2.03 to 1.01, p < 0.05.Decreased circulating hCD4 cells in the peripheral blood. Decreased in the proportion of T cells in the bone marrow and lung. Increased in the total number of human CD45+ cells infiltrating the lamina propria of the small intestine.
体外研究：
Teplizumab (10 ng/mL-10 μg/mL, 5 days) induces human CD8+ T-cell proliferation. Teplizumab (6 days) increases the expression of CD25 and intracellular CTLA4 on CD8+ cells (freshly isolated PBMCs).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备